EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

M. avium Complex Pulmonary Infections: Therapeutic Obstacles and Progress in Drug Development

Elise Si Ahmed Charrier iD, Alexandra Dassonville-Klimpt iD, Claire Andréjak, Pascal Sonnet iD

Pharmaceuticals · 13.06.2025 · 18 (6) · 891

DOI: 10.3390/ph18060891 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 13.06.2025. Verfasst von Elise Si Ahmed Charrier und 3 weiteren Autor:innen. Beteiligte Einrichtung: Agents Infectieux, Résistance et Chimiothérapie, AGIR, Université de Picardie-Jules-Verne, UR 4294, UFR de Pharmacie, 1 Rue des Louvels, CEDEX 1, 800…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Université de Picardie Jules Verne, Fédération Hospitalo-Universitaire RESPIRE., Elise Si Ahmed Charrier.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Worldwide, several million people are infected with mycobacteria such as Mycobacterium tuberculosis (M. tb) or non-tuberculous mycobacteria (NTM). In 2023, 10.8 million cases and 1.25 million deaths due to M. tb were recorded. In Europe and North America, the emergence of NTM is tending to outstrip that of M. tb. Among pulmonary NTM, Mycobacterium avium complex (MAC) is the most common, accounting for 80% of NTM infections. First-line treatment requires the combination of at least three antibiotics over a long period and with different mechanisms of action to limit cross-resistance. The challenge is to discover more effective new anti-MAC molecules to reduce the duration of treatment and to overcome resistant strains. The aim of this review is to present an overview of the challenges posed by MAC infection such as side effects, reinfections and resistance mechanisms. The latest therapeutic options such as the optimized combination therapy, drug repurposing and the development of new formulations, as well as new anti-MAC compounds currently in (pre)clinical trials will also be discussed.

Schlagwörter

Stichwörter der Autor:innen

Mycobacterium avium complexanti-MAC compoundsclinical trialsdrug developmentnon-tuberculous mycobacteria

Autor:innen und Institutionen

  • Agents Infectieux, Résistance et Chimiothérapie, AGIR, Université de Picardie-Jules-Verne, UR 4294, UFR de Pharmacie, 1 Rue des Louvels, CEDEX 1, 80037 Amiens, France.
  • Service de Pneumologie, CHU Amiens-Picardie, 80000 Amiens, France.

ORCID-Profile: Elise Si Ahmed Charrier, Alexandra Dassonville-Klimpt, Pascal Sonnet

Förderung

  • Université de Picardie Jules Verne
  • Fédération Hospitalo-Universitaire RESPIRE.
  • Elise Si Ahmed Charrier

Zitieren

APA

Charrier, E. S. A., Dassonville-Klimpt, A., Andréjak, C., & Sonnet, P. (2025). M. avium Complex Pulmonary Infections: Therapeutic Obstacles and Progress in Drug Development. Pharmaceuticals, 18(6), 891. https://doi.org/10.3390/ph18060891

Vancouver

Charrier ESA, Dassonville-Klimpt A, Andréjak C, Sonnet P. M. avium Complex Pulmonary Infections: Therapeutic Obstacles and Progress in Drug Development. Pharmaceuticals. 2025;18(6):891. doi:10.3390/ph18060891

BibTeX
@article{Charrier2025,
  author = {Charrier, Elise Si Ahmed and Dassonville-Klimpt, Alexandra and Andréjak, Claire and Sonnet, Pascal},
  title = {M. avium Complex Pulmonary Infections: Therapeutic Obstacles and Progress in Drug Development},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {6},
  pages = {891},
  doi = {10.3390/ph18060891}
}
Kostenlos starten →